Personalis reported strong revenue growth and significant progress in molecular test delivery and biopharma revenue. The company maintains a healthy cash position and positive guidance for 2025. However, high operating expenses and net loss, alongside the impact of unreimbursed clinical test costs on gross margin, present challenges. Overall, the sentiment leans positive due to the outweighing highlights and the strategic steps towards future reimbursement and revenue growth.

Company Guidance -

Q1 2025

During the first quarter of 2025, Personalis reported revenues of $20.6 million, delivering over 2,000 molecular tests. The company is projecting revenues between $80 million and $90 million for the full year, with a growth expectation of 30% to 40% quarter-over-quarter in molecular results. Cash and cash equivalents stood at $185.7 million, providing a strong runway to pursue growth objectives. The biopharma segment contributed $13.6 million, marking a 39% increase from the prior year, driven by the adoption of NeXT Personal. Clinical diagnostics achieved their highest quarterly revenue, and Personalis reiterated its goal of achieving reimbursement for at least two indications in 2025. The company aims to expand market presence through partnerships, such as with Tempus, while also advancing research to support reimbursement efforts, particularly in breast, lung, and colorectal cancers.

Strong Revenue Growth and Molecular Test Delivery

Personalis achieved revenues of over $20 million in Q1 2025 and delivered over 2,000 molecular tests, marking a 52% increase from the previous quarter and approximately 650% year-over-year growth compared to Q1 2024.

Biopharma Revenue Surge

Biopharma revenue grew to $13.6 million, a 39% increase compared to the same period in 2024, driven by strong growth in the use of NeXT Personal.

Cash Position and Financial Guidance

The company has cash and cash equivalents of $185.7 million, reiterating revenue guidance of $80 million to $90 million for 2025, with expected 30% to 40% quarter-over-quarter growth in molecular results.

Clinical and Reimbursement Progress

Personalis is advancing towards reimbursement in breast, lung cancer, and IO therapy monitoring, with promising interim data in colorectal cancer indicating potential for future reimbursement.

Personalis (PSNL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PSNL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 06, 2025	2025 (Q2)	-0.24 / -	-0.24	―	―	―
May 06, 2025	2025 (Q1)	-0.25 / -0.18	-0.26	30.77% (+0.08)	―
Feb 27, 2025	2024 (Q4)	-0.28 / -0.23	-0.54	57.41% (+0.31)	―
Nov 06, 2024	2024 (Q3)	-0.35 / -0.64	-0.6	-6.67% (-0.04)	―
Aug 07, 2024	2024 (Q2)	-0.37 / -0.24	-0.5	52.00% (+0.26)	―
May 08, 2024	2024 (Q1)	-0.41 / -0.26	-0.61	57.38% (+0.35)	―
Feb 28, 2024	2023 (Q4)	-0.50 / -0.54	-0.67	19.40% (+0.13)	―
Nov 07, 2023	2023 (Q3)	-0.52 / -0.60	-0.58	-3.45% (-0.02)	―
Aug 08, 2023	2023 (Q2)	-0.54 / -0.50	-0.6	16.67% (+0.10)	―
May 03, 2023	2023 (Q1)	-0.58 / -0.61	-0.63	3.17% (+0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PSNL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 06, 2025	$4.00	$4.84	+21.00%
Feb 27, 2025	$4.24	$4.14	-2.36%
Nov 06, 2024	$5.58	$4.32	-22.58%
Aug 07, 2024	$2.88	$3.43	+19.10%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Personalis Inc (PSNL) report earnings?

Personalis Inc (PSNL) is schdueled to report earning on Aug 06, 2025, After Close (Confirmed).

What is Personalis Inc (PSNL) earnings time?

Personalis Inc (PSNL) earnings time is at Aug 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PSNL EPS forecast?

PSNL EPS forecast for the fiscal quarter 2025 (Q2) is -0.24.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing